사진 확대

South Korean space startup "SpaceLintec" has succeeded in attracting a total of 4 billion won in investment. SpaceLintec is aiming to produce space medicines in 2026. In May this year, it will demonstrate a space medicine platform in Earth's orbit.

SpaceLintec announced on the 11th that it has attracted 2 billion won in Series A investment from Woori Venture Partners and Company K Partners, respectively. SpaceLintec has received a seed investment from Sunbo Angel Partners. With this Series A investment, it has attracted a cumulative 4.3 billion won.

"SpaceLintec is a space medicine company established based on the expertise of CEO Yoon Hak-soon, who has conducted space medicine research with NASA and others, and has infinite growth potential to expand space utilization to the bio sector," said Lee Kang-soo, CEO of Company K Partners, who was in charge of the investment.

SpaceLintec is a company founded in 2021. It was founded by Yoon Hak-soon, a professor at the University of Virginia-Nofok State in the United States. We develop a satellite and space station-based space medicine research and production platform using microgravity environments.

The platform under development will be equipped with space new drug development devices based on joint research results with the Korea Biotechnology Research Institute, Harvard University Medical School, and the Korea Advanced Institute of Science and Technology (KAIST), the company said. "The devices aim to reduce the cost of developing new drugs and shorten the period by utilizing the microgravity of space."

The developed platform is scheduled to be launched in May on a rocket from domestic space launch vehicle startup 'Peridge Aerospace'. An official from SpaceLintec said, "It will be launched on May 27th. We will verify that the developed platform is working well."